GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction

Subodh Verma¹, David A Hess²

Affiliations

¹ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
² Department of Physiology and Pharmacology, Western University, London, ON, Canada; Robarts Research Institute, London, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: dhess3@uwo.ca.

PMID: 40466625
DOI: 10.1016/j.cmet.2025.05.001

GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction

Subodh Verma et al. Cell Metab. 2025.

. 2025 Jun 3;37(6):1257-1259.

doi: 10.1016/j.cmet.2025.05.001.

Authors

Subodh Verma¹, David A Hess²

Affiliations

¹ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
² Department of Physiology and Pharmacology, Western University, London, ON, Canada; Robarts Research Institute, London, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: dhess3@uwo.ca.

PMID: 40466625
DOI: 10.1016/j.cmet.2025.05.001

Abstract

With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al.¹ demonstrated that semaglutide improved walking capacity and hemodynamic parameters and slowed PAD progression in patients with T2D. These results reveal an unanticipated vasculoprotective benefit of GLP-1RAs.

Published by Elsevier Inc.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.V. reports receiving grants and/or research support and/or speaking honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Heart Research Center, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management Inc., Sanofi, and Sun Pharma.

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction

Affiliations

GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction

Authors

Affiliations

Abstract

Conflict of interest statement

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical